In contrast, IL-17A and IL-33 levels decreased progressively with declining tumor differentiation, which may indicate their involvement in early stage inflammatory signaling and the subsequent suppression of immune responses in more advanced cancer. This evidence concerns the gene IL17A and neoplasm.